TAF vs TDF antiviral treatment during pregnancy for hepatitis B
Treatments studied
Part of Digestive system, Infections clinical trials.
This study compares two antiviral medications (TAF and TDF) in pregnant women with hepatitis B to see which is safer and more effective during pregnancy and for the baby's health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female, age 20–40 years old
- You have tested positive for hepatitis B for at least 6 months
- You are currently pregnant (0–24 weeks) and meet guidelines for needing antiviral treatment
- You are willing to take one tablet by mouth every day from now until delivery
- You do not have other serious liver diseases, heart/lung/kidney problems, or uncontrolled conditions like diabetes or high blood pressure
- You can attend all scheduled follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a hepatitis B medicine called TAF in pregnant women who need antiviral treatment. It helps protect both mom and baby from complications of the virus.
This trial tests if TAF is safer and as effective as TDF for pregnant women with high hepatitis B viral loads to prevent passing the virus to their babies. You may qualify if you are pregnant, between 20-28 weeks, and have high viral levels.
This trial studies how well nucleoside (nucleoside-acid) type antiviral medicines control hepatitis B in people whose liver enzyme test (ALT) is currently normal. It may help those with active hepatitis B but no major liver inflammation on recent bloodwork.
This study tests tenofovir alafenamide (TAF) to lower hepatitis B in pregnant people and reduce the chance of passing it to the baby. You may be able to join if you’re pregnant with active hepatitis B and meet safety lab and pregnancy ultrasound requirements.
This study compares two ways of treating hepatitis B in pregnant women to prevent passing the virus to their babies. It tests whether a standard universal treatment approach works better than a quick, point-of-care test-based strategy.
This study tests whether the medicine tenofovir disoproxil can help prevent passing hepatitis B from mother to baby during pregnancy. It is for pregnant women with an active hepatitis B infection who are early in their pregnancy (less than 24 weeks).
Hear when a new Hepatitis B Virus Infection; Pregnant Women trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.